[Form 4] Structure Therapeutics Inc. American Insider Trading Activity

Rhea-AI Filing Summary

FMR LLC, identified as a 10% owner of Structure Therapeutics Inc. (GPCR), filed a Form 4 reporting an open-market sale on 07/30/2025.

• Securities sold: 26,310 American Depositary Shares (ADS), each representing three ordinary shares.
• Sale price: $17.87 per ADS, implying cash proceeds of roughly $470 k.
• Post-sale indirect holdings: 1,515,558 ADS plus 575,934 ordinary shares (45,120 held by F-Prime Capital Partners Life Sciences Advisors Fund VI LP and 530,814 held by F-Prime Capital Partners Life Sciences Fund VI LP).
• The filing notes that Abigail P. Johnson is a director, Chairman and CEO of FMR LLC and that members of the Johnson family collectively control 49% of FMR’s voting power.

No acquisitions were reported; the sole transaction was the ADS disposition coded “S.” FMR and its affiliated funds remain above the 10% beneficial-ownership threshold.

Positive

• None.

Negative

• 10% owner FMR LLC sold 26,310 ADS (≈$470 k) at $17.87, reducing its stake and potentially signaling diminished short-term conviction.

Insights

Securities Analyst

TL;DR: Insider sale by 10% owner; size modest vs. remaining stake, marginally negative signal.

The 26,310-ADS sale equals about 1.7% of FMR’s total reported ADS position. While the amount is immaterial to FMR’s overall ownership—post-trade holdings of 1.52 million ADS still translate to significant influence—the reduction may be interpreted as slight profit-taking. No accompanying purchase offsets the sale, and no explanatory remarks (e.g., option exercise, tax) are given. Because FMR remains a controlling shareholder, the market impact is likely limited but directionally negative.

Portfolio Manager

TL;DR: Minor trim by long-term holder; unlikely to change float materially.

The transaction frees less than half a million dollars and reduces indirect exposure by fewer than 80 k ordinary shares. With continued ownership above 10%, governance influence and strategic alignment appear unchanged. For liquidity analysis, the added float is negligible relative to GPCR’s average daily volume, so pressure on near-term price should be minimal. Nevertheless, some investors view any insider sale—especially by a large holder—as a cautionary datapoint.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FMR LLC

(Last) (First) (Middle)

245 SUMMER STREET

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remark 1

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								45,120	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Ordinary Shares								530,814	I	F-Prime Capital Partners Life Sciences Fund VI LP

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(1)	07/30/2025		S			26,310	(1)	(1)	Ordinary Shares	78,930	$17.87	1,515,558	I	Shares held by persons and entities whose shares are subject to reporting by the undersigned
American Depositary Shares	(1)							(1)	(1)	Ordinary Shares	4,095		1,365	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
American Depositary Shares	(1)							(1)	(1)	Ordinary Shares	48,249		16,083	I	F-Prime Capital Partners Life Sciences Fund VI LP

Explanation of Responses:

1. Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.

	/s/ Richard Bourgelas, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson	08/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Structure Therapeutics (GPCR) ADS did FMR LLC sell?

FMR LLC disposed of 26,310 American Depositary Shares on 07/30/2025.

What price did the GPCR ADS sell for?

The shares were sold at $17.87 per ADS.

How many GPCR ADS does FMR LLC still own after the sale?

The filing shows 1,515,558 ADS remain under FMR LLC’s indirect ownership.

Does FMR LLC remain a 10% owner of Structure Therapeutics?

Yes. Even after the sale, FMR LLC’s aggregate holdings keep it above the 10% ownership threshold.

Were any GPCR shares acquired in this Form 4 filing?

No acquisitions were reported; the filing only shows a sale coded "S".